Citius Oncology (CTOR) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing targeted oncology therapies, with lead product LYMPHIR approved by the FDA in August 2024 for persistent or recurrent CTCL, a rare non-Hodgkin lymphoma.

• LYMPHIR targets a market estimated to exceed $400 million, considered underserved by current treatments.

• Originated from a merger and reorganization involving Citius Pharmaceuticals, TenX Keane Acquisition, and SpinCo, with Citius Pharma retaining significant control.

• Operates under a shared services agreement with Citius Pharma for management and scientific support.

Financial performance and metrics

• No current revenue generation; business activities have focused on planning and R&D.

• July 2025 financing raised approximately $7.44 million through the sale of 6,818,182 shares and warrants at $1.32 per unit.

• As of August 31, 2025, 78,370,584 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including commercialization of LYMPHIR, milestone and royalty payments, and working capital.

• Pending allocation, proceeds will be invested in short-term, investment-grade, interest-bearing securities.